OncoMatch/Clinical Trials/NCT07079423
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Is NCT07079423 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Teclistamab (Tec) for al amyloidosis.
Treatment: Teclistamab (Tec) — This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Disease stage
Required: Stage IIIB
Lab requirements
Blood counts
neutrophil ≥ 1×10E9/L, hemoglobin ≥ 8g/dL, platelet ≥ 75×10E9/L
Kidney function
estimated glomerular filtration rate ≥ 20 mL/min, not receiving renal replacement therapy
Liver function
ALT or AST ≤ 5 × ULN, total bilirubin ≤ 2 × ULN
Neutrophil <1×10E9/L, hemoglobin < 8g/dL, or platelet < 75×10E9/L. Severely compromised hepatic or renal function: ALT or AST > 5 × ULN, total bilirubin > 2 × ULN, estimated glomerular filtration rate < 20 mL/min, or receiving renal replacement therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07079423 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IIIB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages